Focus: AbCellera is a therapeutic antibody discovery biotech founded in 2015, leveraging AI and proprietary platform technology to identify novel monoclonal antibodies across multiple therapeutic areas. The company operates at mid-stage scale with 501-1000 employees headquartered in Vancouver.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Stable — net -4 jobs in 30d
7 added, 11 removed. Backfill posture.
Best suited for scientists and early-career professionals seeking exposure to AI-enabled discovery platforms and antibody technology, but clinical development professionals should assess pipeline depth and company cash position before committing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for AbCellera
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AbCellera's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Forget AI Stocks: This Pharma Giant Is Using AI to Dominate Drug Discovery - The Motley Fool
Forget AI Stocks: This Pharma Giant Is Using AI to Dominate Drug Discovery The Motley Fool
AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets - simplywall.st
AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets simplywall.st
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo